Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1927 1
1955 1
1991 1
1992 2
2001 2
2011 1
2012 1
2015 1
2018 1
2019 3
2020 6
2021 7
2022 6
2023 2
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update.
Cooke GS, Flower B, Cunningham E, Marshall AD, Lazarus JV, Palayew A, Jia J, Aggarwal R, Al-Mahtab M, Tanaka Y, Jeong SH, Poovorawan K, Waked I, Hiebert L, Khue PM, Grebely J, Alcantara-Payawal D, Sanchez-Avila JF, Mbendi C, Muljono DH, Lesi O, Desalegn H, Hamid S, de Araujo A, Cheinquer H, Onyekwere CA, Malyuta R, Ivanchuk I, Thomas DL, Pimenov N, Chulanov V, Dirac MA, Han H, Ward JW. Cooke GS, et al. Among authors: flower b. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):346-365. doi: 10.1016/S2468-1253(23)00321-7. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367629 Review.
Spots of bother.
Morgan SM, Flower B, Samaan MA. Morgan SM, et al. Among authors: flower b. BMJ Case Rep. 2015 Dec 16;2015:bcr2015212721. doi: 10.1136/bcr-2015-212721. BMJ Case Rep. 2015. PMID: 26677155 Free PMC article. No abstract available.
Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.
Cooke GS, Hung LM, Flower B, McCabe L, Hang VTK, Thu VT, Thuan DT, Dung NT, Phuong LT, Khoa DB, An NTC, Thach PN, Huong VTT, Bich DT, Tuyen NK, Ansari MA, Le Ngoc C, Quang VM, Phuong NTN, Thao LT, Tran NB, Kestelyn E, Kingsley C, Van Doorn R, Rahman M, Pett SL, Thwaites GE, Barnes E, Day JN, Chau NVV, Walker AS. Cooke GS, et al. Among authors: flower b. Lancet. 2025 May 17;405(10491):1769-1780. doi: 10.1016/S0140-6736(25)00097-2. Epub 2025 May 8. Lancet. 2025. PMID: 40347964 Free article. Clinical Trial.
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions.
Marshall AD, Willing AR, Kairouz A, Cunningham EB, Wheeler A, O'Brien N, Perera V, Ward JW, Hiebert L, Degenhardt L, Hajarizadeh B, Colledge S, Hickman M, Jawad D, Lazarus JV, Matthews GV, Scheibe A, Vickerman P, Dore GJ, Grebely J; Global HCV and HIV Treatment Restrictions Group. Marshall AD, et al. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):366-382. doi: 10.1016/S2468-1253(23)00335-7. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367631 Review.
VirA+EmiC project: Evaluating real-world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department.
Nebbia G, Ruf M, Hunter L, Balasegaram S, Wong T, Kulasegaram R, Surey J, Khan Z, Williams J, Karo B, Snell L, Flower B, Evans H, Douthwaite S. Nebbia G, et al. Among authors: flower b. J Viral Hepat. 2022 Jul;29(7):559-568. doi: 10.1111/jvh.13676. Epub 2022 Apr 9. J Viral Hepat. 2022. PMID: 35357750 Free PMC article.
37 results